Supernus Pharmaceuticals, Inc.
SUPN
$32.22
$0.872.78%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 661.82M | 651.97M | 630.16M | 597.40M | 607.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 661.82M | 651.97M | 630.16M | 597.40M | 607.52M |
| Cost of Revenue | 77.91M | 71.44M | 73.45M | 76.63M | 83.78M |
| Gross Profit | 583.91M | 580.54M | 556.71M | 520.77M | 523.74M |
| SG&A Expenses | 335.28M | 334.96M | 336.40M | 337.28M | 336.36M |
| Depreciation & Amortization | 77.98M | 80.80M | 82.56M | 82.56M | 82.39M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 599.96M | 590.69M | 589.53M | 591.78M | 594.12M |
| Operating Income | 61.86M | 61.28M | 40.64M | 5.63M | 13.40M |
| Income Before Tax | 97.87M | 72.48M | 37.42M | -6.01M | 2.77M |
| Income Tax Expenses | 24.01M | 12.77M | 32.19M | 9.50M | 1.45M |
| Earnings from Continuing Operations | 73.87 | 59.71 | 5.24 | -15.51 | 1.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.87M | 59.71M | 5.24M | -15.51M | 1.32M |
| EBIT | 61.86M | 61.28M | 40.64M | 5.63M | 13.40M |
| EBITDA | 142.27M | 144.53M | 125.64M | 90.63M | 98.26M |
| EPS Basic | 1.34 | 1.08 | 0.09 | -0.28 | 0.03 |
| Normalized Basic EPS | 0.88 | 0.85 | 0.59 | 0.15 | 0.25 |
| EPS Diluted | 1.32 | 1.07 | 0.09 | -0.29 | -0.01 |
| Normalized Diluted EPS | 0.87 | 0.84 | 0.58 | 0.15 | 0.23 |
| Average Basic Shares Outstanding | 220.40M | 219.58M | 219.04M | 218.56M | 218.14M |
| Average Diluted Shares Outstanding | 223.83M | 222.67M | 221.26M | 220.04M | 226.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |